Phase I and clinical pharmacology study of bevacizumab, sorafenib, and low-dose cyclophosphamide in children and young adults with refractory/recurrent solid tumors
Fariba Navid, Sharyn D. Baker, M. Beth McCarville, Clinton F. Stewart, Catherine A. Billups, Jianrong Wu, Andrew M. Davidoff, Sheri L. Spunt, Wayne L. Furman, Lisa M. McGregor, Shuiying Hu, John C. Panetta, David Turner, Demba Fofana, Wilburn E. Reddick, Wing Leung, Victor M. Santana
Research output: Contribution to journal › Article › peer-review
62Scopus
citations
Fingerprint
Dive into the research topics of 'Phase I and clinical pharmacology study of bevacizumab, sorafenib, and low-dose cyclophosphamide in children and young adults with refractory/recurrent solid tumors'. Together they form a unique fingerprint.